MGMT and central nervous system cancer: O6-methylguanine-DNA methyltransferase-encoding gene (MGMT) is used as a predictive marker for response to temozolomide (TMZ) in patients with gliomas, where hypermethylation of the MGMT promoter is associated with increased efficacy of TMZ6,7.